Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
MediciNova, Inc. (MNOV)
USD1.40
+0.03 (+2.19%)
US NASDAQ Healthcare Biotechnology
Address
4275 Executive Square 92037
La Jolla, CA, US
La Jolla, CA, US
CEO
Yuichi Iwaki
Website
medicinova.com
IPO
2006-12-08
CIK 1226616 ISIN US58468P2065
Also trades on
NASDAQ Global Market · MNOV (USD)
Tokyo Stock Exchange · 4875.T (JPY)
Description
MediciNova, Inc. is a biopharmaceutical firm dedicated to discovering and advancing innovative small molecule therapies for severe illnesses where current treatments are insufficient within the United States. Its robust development pipeline features MN-166 (ibudilast), an oral agent with both anti-inflammatory and neuroprotective properties, currently being investigated for a range of neurological conditions. These include primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and various forms of substance dependence and addiction. The company's portfolio also comprises MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist aimed at treating acute asthma attacks; MN-001 (tipelukast), an orally available small molecule designed for fibrotic disorders like nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent intended for solid tumor oncology. MediciNova has established strategic partnerships with companies such as Kissei Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Angiogene Pharmaceuticals Ltd., and Meiji Seika Kaisha Ltd. Established in 2000, the company's headquarters are situated in La Jolla, California.
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Ticker | Date | Filing |
|---|---|---|---|
| Avigen | 4875 | 2009-09-17 | View |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.40
+0.03 (+2.19%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
41.2K
Beta
0.62
Float Shares
42.26M
Free Float %
85.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.19% | -1.41% | -0.71% | -5.41% | -9.68% | +6.87% | +2.19% | -36.51% | -66.35% | -77.49% | -87.21% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (4 ratings, all time)
Buy
Price Targets & DCF
Current price
1.40
DCF (Unlevered)
0.61
-56.1%
DCF (Levered)
0.62
-55.6%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 3 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-13.75
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-4.4% Q1'26: +14.4% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-2,811.6% Q1'26: -1.1% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-2,927.3% Q1'26: +0.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-109.3% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.0% ★ Q1'26: +0.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.02×
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2019 actual |
Dec 2021 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 2 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 3 Rev. Ana. 3 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 19.13M (-100.0%)
|
4.04M
est: 4.01M (+0.6%)
|
1.00M
est: 1.00M (+0.0%)
|
—
est: 134.6K (-100.0%)
|
409.7K
est: 150.0K (+173.1%)
|
166.7K
166.7K – 166.7K
+11.1% YoY
|
700.0K
700.0K – 700.0K
+320.0% YoY
|
42.69M
42.69M – 42.69M
+5,998.6% YoY
|
97.61M
97.61M – 97.61M
+128.6% YoY
|
202.19M
202.19M – 202.19M
+107.1% YoY
|
| EBITDA |
-14.01M
est: 3.83M (-466.0%)
|
-10.19M
est: 802.5K (-1,369.7%)
|
-9.88M
est: -200.0K (-4,840.0%)
|
-12.65M
est: -26.9K (-46,908.6%)
|
-11.97M
est: -30.0K (-39,807.5%)
|
-33.3K
-33.3K – -33.3K
-11.1% YoY
|
-140.0K
-140.0K – -140.0K
-320.0% YoY
|
-8.54M
-8.54M – -8.54M
-5,998.7% YoY
|
-19.52M
-19.52M – -19.52M
-128.6% YoY
|
-40.44M
-40.44M – -40.44M
-107.1% YoY
|
| EBIT |
-14.03M
est: 3.83M (-466.7%)
|
-10.22M
est: 802.5K (-1,372.9%)
|
-9.90M
est: -200.0K (-4,850.2%)
|
-12.68M
est: -26.9K (-46,986.9%)
|
-11.99M
est: -30.0K (-39,874.5%)
|
-33.3K
-33.3K – -33.3K
-11.1% YoY
|
-140.0K
-140.0K – -140.0K
-320.0% YoY
|
-8.54M
-8.54M – -8.54M
-5,998.7% YoY
|
-19.52M
-19.52M – -19.52M
-128.6% YoY
|
-40.44M
-40.44M – -40.44M
-107.1% YoY
|
| Net Income |
-12.94M
est: -17.09M (+24.3%)
|
-10.13M
est: -12.42M (+18.4%)
|
-8.57M
est: -8.17M (-4.9%)
|
-11.05M
est: -10.79M (-2.4%)
|
-12.00M
est: -18.64M (+35.6%)
|
-14.96M
-14.96M – -14.96M
+19.7% YoY
|
-19.63M
-19.63M – -19.63M
-31.1% YoY
|
-10.66M
-21.59M – 14.23M
+45.7% YoY
|
32.55M
32.55M – 32.55M
+405.2% YoY
|
78.50M
78.50M – 78.50M
+141.2% YoY
|
| SGA |
7.95M
est: 36.96M (-78.5%)
|
5.72M
est: 7.75M (-26.3%)
|
5.24M
est: 4.74M (+10.6%)
|
5.48M
est: 637.8K (+759.3%)
|
6.16M
est: 710.8K (+766.5%)
|
789.8K
789.8K – 789.8K
+11.1% YoY
|
3.32M
3.32M – 3.32M
+320.0% YoY
|
202.29M
202.29M – 202.29M
+5,998.6% YoY
|
462.54M
462.54M – 462.54M
+128.6% YoY
|
958.09M
958.09M – 958.09M
+107.1% YoY
|
| EPS |
-0.30
est: -0.35 (+13.9%)
|
-0.21
est: -0.25 (+17.1%)
|
-0.17
est: -0.17 (-2.1%)
|
-0.23
est: -0.22 (-4.5%)
|
-0.24
est: -0.38 (+36.8%)
|
-0.31
-0.31 – -0.31
+19.7% YoY
|
-0.40
-0.40 – -0.40
-31.1% YoY
|
-0.11
-0.44 – 0.29
+72.5% YoY
|
0.66
0.66 – 0.66
+703.0% YoY
|
1.60
1.60 – 1.60
+141.2% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-04 | D. Boral Capital | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-11 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-08 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-07 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-06 | B- | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-01 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-9.81M
OE per share TTM
-0.20
Owner's Yield
-14.48%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
55.4%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
10
Total invested
3.31M
Insider transactions (90d)
0
Beneficial owners (>5%)
36
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Essex Woodlands Health Ventures Fund VI, L.P. | 11.70M | 11.84% | — | — | — | — | PN | : | 2006-02-13 | ↗ |
| 2 | Essex Woodlands Health Ventures VI, L.L.C. | 11.70M | 11.84% | — | — | — | — | OO | : | 2006-02-13 | ↗ |
| 3 | Essex Woodlands Health Ventures VI, L.P. | 11.70M | 11.84% | — | — | — | — | OO | : | 2006-02-13 | ↗ |
| 4 | Immanuel Thangaraj | 11.70M | 11.84% | — | — | — | — | IN | : | 2006-02-13 | ↗ |
| 5 | Mark Pacala | 11.70M | 11.84% | — | — | — | — | IN | : | 2006-02-13 | ↗ |
| 6 | Martin P. Sutter | 11.70M | 11.84% | — | — | — | — | IN | : | 2006-02-13 | ↗ |
| 7 | Petri Vainio, MD, Ph.D. | 11.70M | 11.84% | — | — | — | — | IN | : | 2006-02-13 | ↗ |
| 8 | 3D Investment Partners Pte. Ltd. | 5.50M | 11.30% | — | 5.50M | — | 5.50M | IA, OO | Singapore | 2021-01-21 | ↗ |
| 9 | 3D Opportunity Master Fund | 5.50M | 11.30% | — | 5.50M | — | 5.50M | OO | Cayman Islands | 2021-01-21 | ↗ |
| 10 | Edward C. Johnson 3d | 3.51M | 11.73% | — | — | 3.51M | — | IN | Delaware | 2015-09-10 | ↗ |
| 11 | Hajime Satomi | 2.22M | 10.00% | 2.22M | — | 2.22M | — | IN | Japan | 2013-05-20 | ↗ |
| 12 | Samurai Investments San Diego LLC | 1.75M | 8.00% | 1.75M | — | 1.75M | — | OO | Japan | 2013-05-20 | ↗ |
| 13 | Inc. | 1.46M | 10.70% | — | 1.46M | — | — | CO | Illinois | 2009-12-24 | ↗ |
| 14 | N. Lampert | 1.46M | 10.70% | — | 1.46M | — | — | IN | Illinois | 2009-12-24 | ↗ |
| 15 | Partners L.P. | 1.46M | 10.70% | — | 1.46M | — | — | IA | Illinois | 2009-12-24 | ↗ |
| 16 | (1) BlackRock, Inc. | 1.13M | 2.30% | 1.13M | — | 1.13M | — | HC | Delaware | 2021-07-12 | ↗ |
| 17 | Cummings Bay Capital Management GP, LLC | 913.0K | 5.60% | — | 913.0K | — | — | HC, OO | Delaware | 2012-02-09 | ↗ |
| 18 | Cummings Bay Capital Management, L.P. | 913.0K | 5.60% | — | 913.0K | — | — | IA, PN | Delaware | 2012-02-09 | ↗ |
| 19 | Highland Capital Management Services, Inc. | 913.0K | 5.60% | — | 913.0K | — | — | HC, CO | Delaware | 2012-02-09 | ↗ |
| 20 | James D. Dondero | 913.0K | 5.60% | — | 913.0K | — | — | HC, IN | United States | 2012-02-09 | ↗ |
| 21 | Southpaw Credit Opportunity Master Fund LP | 873.1K | 6.60% | — | 873.1K | — | 873.1K | PN | Cayman Islands | 2011-01-19 | ↗ |
| 22 | Pyxis Capital, L.P. (f/k/a Highland Funds Asset Management, L.P.) | 843.4K | 5.20% | — | 843.4K | — | — | IA, PN | Delaware | 2012-02-09 | ↗ |
| 23 | Pyxis Long/Short Healthcare Fund (f/k/a Highland Long/Short Healthcare Fund) | 843.4K | 5.20% | 843.4K | — | 843.4K | — | IV, OO | Delaware | 2012-02-09 | ↗ |
| 24 | Strand Advisors XVI, Inc. | 843.4K | 5.20% | — | 843.4K | — | — | HC, CO | Delaware | 2012-02-09 | ↗ |
| 25 | Investments, L.L.C. | 821.2K | 6.30% | — | 821.2K | — | — | OO | Illinois | 2009-12-24 | ↗ |
| 26 | Yuichi Iwaki | 767.7K | 6.40% | 767.7K | — | 767.7K | — | IN | Japan | 2008-02-11 | ↗ |
| 27 | JAFCO G-9(A) Venture Capital Investment Limited Partnership | 415.7K | 4.21% | 415.7K | — | 415.7K | — | PN | Citizenship or Place of Organization | 2007-02-14 | ↗ |
| 28 | Value Fund, L.P. | 325.4K | 2.60% | — | 325.4K | — | — | PN | Illinois | 2009-12-24 | ↗ |
| 29 | JAFCO G-9(B) Venture Capital Investment Limited Partnership | 278.0K | 2.81% | 278.0K | — | 278.0K | — | PN | Citizenship or Place of Organization | 2007-02-14 | ↗ |
| 30 | Value Fund II, L.P. | 224.9K | 1.80% | — | 224.9K | — | — | PN | Illinois | 2009-12-24 | ↗ |
| 31 | 10, L.L.C. | 84.1K | 1.00% | — | 84.1K | — | — | OO | Illinois | 2009-12-24 | ↗ |
| 32 | Howard Golden | — | 0.00% | — | — | — | — | IN | : | 2012-01-23 | ↗ |
| 33 | Kevin Wyman | — | 0.00% | — | — | — | — | IN | : | 2012-01-23 | ↗ |
| 34 | Southpaw Asset Management LP | — | 0.00% | — | — | — | — | PN | : | 2012-01-23 | ↗ |
| 35 | Southpaw Credit Opportunity Master Fund L.P. | — | 0.00% | — | — | — | — | PN | : | 2012-01-23 | ↗ |
| 36 | Southpaw Holdings LLC | — | 0.00% | — | — | — | — | OO | : | 2012-01-23 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
10
-23 vs prev Q
New positions
3
Closed positions
26
Increased
3
Reduced
5
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | ESSEX WOODLANDS MANAGEMENT, INC. | 1.11M +— (+0.0%) | 1.45M +44.2K (+3.1%) | 2.25% +0.000 pp | 0.46% -0.002 pp | USD2.64 -50.4% | 51 qtrs — |
| 2 | VANGUARD GROUP INC | 705.6K +5.2K (+0.7%) | 924.4K +41.9K (+4.7%) | 1.44% +0.011 pp | 0.00% +0.000 pp | USD5.66 -76.9% | 64 qtrs — |
| 3 | BLACKROCK, INC. | 705.0K +6.0K (+0.9%) | 923.5K +35.8K (+4.0%) | 1.44% +0.012 pp | 0.00% +0.000 pp | USD2.09 -37.3% | 6 qtrs — |
| 4 | CITIGROUP INC | 635.7K +41.7K (+7.0%) | 832.8K +84.3K (+11.3%) | 1.30% +0.085 pp | 0.00% +0.000 pp | USD3.97 -67.0% | 40 qtrs — |
| 5 | DRW SECURITIES, LLC | 3.8K +3.8K (+100.0%) | 820.8K +820.8K (+100.0%) | 0.01% +0.008 pp | 0.02% +0.022 pp | USD1.31 +0.0% | 1 qtrs NEW |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 529.6K -119.0 (0.0%) | 693.9K +26.3K (+3.9%) | 1.08% 0.000 pp | 0.00% +0.000 pp | USD5.56 -76.4% | 59 qtrs — |
| 7 | UBS GROUP AG | 225.7K +3.4K (+1.5%) | 295.6K +13.3K (+4.7%) | 0.46% +0.007 pp | 0.00% +0.000 pp | USD2.09 -37.3% | 8 qtrs — |
| 8 | RENAISSANCE TECHNOLOGIES LLC | 196.8K +4.3K (+2.2%) | 257.8K +13.3K (+5.5%) | 0.40% +0.009 pp | 0.00% +0.000 pp | USD2.81 -53.4% | 25 qtrs — |
| 9 | STATE STREET CORP | 193.7K +19.1K (+10.9%) | 253.7K +33.8K (+15.3%) | 0.39% +0.039 pp | 0.00% +0.000 pp | USD6.11 -78.6% | 40 qtrs — |
| 10 | JANE STREET GROUP, LLC | 163.1K +163.1K (+100.0%) | 213.7K +213.7K (+100.0%) | 0.33% +0.333 pp | 0.00% +0.000 pp | USD1.31 +0.0% | 1 qtrs NEW |
| 11 | NORTHERN TRUST CORP | 133.2K -1.6K (-1.2%) | 174.4K +3.3K (+1.9%) | 0.27% -0.003 pp | 0.00% +0.000 pp | USD6.92 -81.1% | 51 qtrs — |
| 12 | BANK OF NEW YORK MELLON CORP | 96.2K +— (+0.0%) | 126.0K +3.8K (+3.1%) | 0.20% +0.000 pp | 0.00% +0.000 pp | USD7.01 -81.3% | 40 qtrs — |
| 13 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 76.0K +— (+0.0%) | 99.6K +3.8K (+4.0%) | 0.16% +0.000 pp | 0.00% +0.000 pp | USD4.05 -67.7% | 20 qtrs — |
| 14 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 71.5K +— (+0.0%) | 93.7K +3.6K (+4.0%) | 0.15% +0.000 pp | 0.00% +0.000 pp | USD1.44 -9.0% | 39 qtrs — |
| 15 | DIMENSIONAL FUND ADVISORS LP | 65.0K -1.2K (-1.8%) | 85.2K +1.7K (+2.1%) | 0.13% -0.002 pp | 0.00% +0.000 pp | USD2.67 -50.9% | 24 qtrs — |
| 16 | SBI SECURITIES CO., LTD. | 45.2K -305.0 (-0.7%) | 59.3K +1.4K (+2.5%) | 0.09% -0.001 pp | 0.00% +0.000 pp | USD2.04 -35.8% | 5 qtrs — |
| 17 | TWO SIGMA INVESTMENTS, LP | 39.7K +39.7K (+100.0%) | 52.1K +52.1K (+100.0%) | 0.08% +0.081 pp | 0.00% +0.000 pp | USD1.31 +0.0% | 1 qtrs NEW |
| 18 | BARCLAYS PLC | 39.4K -43.4K (-52.4%) | 51.6K -122.3K (-70.3%) | 0.08% -0.089 pp | 0.00% +0.000 pp | USD3.25 -59.7% | 38 qtrs — |
| 19 | SCHONFELD STRATEGIC ADVISORS LLC | 36.0K +1.4K (+4.0%) | 47.2K +3.2K (+7.3%) | 0.07% +0.003 pp | 0.00% +0.000 pp | USD2.61 -49.8% | 17 qtrs — |
| 20 | BANK OF AMERICA CORP /DE/ | 30.0K -61.5K (-67.2%) | 39.3K -76.9K (-66.2%) | 0.06% -0.125 pp | 0.00% +0.000 pp | USD2.41 -45.6% | 51 qtrs — |
| 21 | LANTERN WEALTH ADVISORS, LLC | 30.0K +30.0K (+100.0%) | 39.3K +39.3K (+100.0%) | 0.06% +0.061 pp | 0.02% +0.021 pp | USD1.31 +0.0% | 1 qtrs NEW |
| 22 | CITADEL ADVISORS LLC | 28.7K -44.2K (-60.6%) | 37.6K -54.2K (-59.0%) | 0.06% -0.090 pp | 0.00% +0.000 pp | USD1.27 +3.1% | 2 qtrs — |
| 23 | GOLDMAN SACHS GROUP INC | 26.5K +26.5K (+100.0%) | 34.7K +34.7K (+100.0%) | 0.05% +0.054 pp | 0.00% +0.000 pp | USD1.31 +0.0% | 1 qtrs NEW |
| 24 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 22.8K -100.1K (-81.5%) | 29.8K -125.0K (-80.7%) | 0.05% -0.204 pp | 0.00% +0.000 pp | USD2.07 -36.7% | 29 qtrs — |
| 25 | STONEX GROUP INC. | 19.2K +19.2K (+100.0%) | 25.2K +25.2K (+100.0%) | 0.04% +0.039 pp | 0.00% +0.001 pp | USD1.31 +0.0% | 1 qtrs NEW |
| 26 | TWO SIGMA ADVISERS, LP | 13.5K +13.5K (+100.0%) | 17.7K +17.7K (+100.0%) | 0.03% +0.028 pp | 0.00% +0.000 pp | USD1.31 +0.0% | 1 qtrs NEW |
| 27 | BUCKINGHAM STRATEGIC PARTNERS | 10.0K +10.0K (+100.0%) | 13.1K +13.1K (+100.0%) | 0.02% +0.020 pp | 0.00% +0.000 pp | USD1.31 +0.0% | 1 qtrs NEW |
| 28 | HANTZ FINANCIAL SERVICES, INC. | 4.3K +— (+0.0%) | 6.0K +1.0K (+20.0%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD1.85 -29.2% | 9 qtrs — |
| 29 | MORGAN STANLEY | 2.0K +— (+0.0%) | 2.6K +80.0 (+3.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.27 +3.1% | 4 qtrs — |
| 30 | TOWER RESEARCH CAPITAL LLC (TRC) | 1.8K -363.0 (-16.4%) | 2.4K -387.0 (-13.8%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD1.96 -33.2% | 23 qtrs — |
| 31 | JPMORGAN CHASE & CO | 576.00 +500.0 (+657.9%) | 755.00 +659.0 (+686.5%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD1.37 -4.4% | 34 qtrs — |
| 32 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 305.00 +— (+0.0%) | 400.00 +13.0 (+3.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD5.05 -74.1% | 20 qtrs — |
| 33 | ADVISOR GROUP HOLDINGS, INC. | 66.00 +66.0 (+100.0%) | 86.00 +86.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.30 +0.8% | 1 qtrs NEW |
| 34 | FMR LLC | — -50.0 (-100.0%) | — -63.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 2 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.01% | 221.0K | 0.60% |
| 2 | Vanguard Extended Market ETF VXF | 0.00% | 809.6K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
7
Sells
0
Shares acquired
973.5K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+973,500
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-16 | Matsuda Kazuko | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 350,000 | 2.10 | 735.0K | 350,000 | D | ↗ |
| 2026-01-16 | IWAKI YUICHI | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 450,000 | 2.10 | 945.0K | 450,000 | D | ↗ |
| 2025-06-17 | Nagao Hideki | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 1.26 | 25.2K | 20,000 | D | ↗ |
| 2025-06-17 | Lemerond Nicole | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 1.26 | 25.2K | 20,000 | D | ↗ |
| 2025-06-17 | BEAVER CAROLYN | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 1.26 | 25.2K | 20,000 | D | ↗ |
| 2025-02-12 | Nagao Hideki | Director | A-Award | A | Stock Option (Right to Buy) | 24,500 | 1.84 | 45.1K | 24,500 | D | ↗ |
| 2025-02-12 | Matsuda Kazuko | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 100,000 | 1.84 | 184.0K | 100,000 | D | ↗ |
| 2025-02-12 | Lemerond Nicole | Director | A-Award | A | Stock Option (Right to Buy) | 24,500 | 1.84 | 45.1K | 24,500 | D | ↗ |
| 2025-02-12 | IWAKI YUICHI | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 100,000 | 1.84 | 184.0K | 100,000 | D | ↗ |
| 2025-02-12 | BEAVER CAROLYN | Director | A-Award | A | Stock Option (Right to Buy) | 24,500 | 1.84 | 45.1K | 24,500 | D | ↗ |
| 2025-01-07 | Matsuda Kazuko | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 300,000 | 1.52 | 456.0K | 300,000 | D | ↗ |
| 2025-01-07 | IWAKI YUICHI | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 400,000 | 1.52 | 608.0K | 400,000 | D | ↗ |
| 2024-06-11 | Nagao Hideki | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 1.34 | 26.8K | 20,000 | — | ↗ |
| 2024-06-11 | Lemerond Nicole | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 1.34 | 26.8K | 20,000 | — | ↗ |
| 2024-06-11 | BEAVER CAROLYN | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 1.34 | 26.8K | 20,000 | — | ↗ |
| 2024-01-09 | OBrien Geoffrey | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 84,000 | 2.40 | 201.6K | 84,000 | — | ↗ |
| 2024-01-09 | Matsuda Kazuko | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 157,500 | 2.40 | 378.0K | 157,500 | — | ↗ |
| 2024-01-09 | IWAKI YUICHI | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 210,000 | 2.40 | 504.0K | 210,000 | — | ↗ |
| 2023-08-04 | Lemerond Nicole | Director | A-Award | A | Stock Option (Right to Buy) | 18,333 | 2.47 | 45.3K | 18,333 | — | ↗ |
| 2023-06-13 | Nagao Hideki | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 2.23 | 44.6K | 20,000 | — | ↗ |
| 2023-06-13 | BEAVER CAROLYN | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 2.23 | 44.6K | 20,000 | — | ↗ |
| 2023-01-23 | OBrien Geoffrey | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 76,950 | 0.00 | — | 76,950 | — | ↗ |
| 2023-01-23 | Matsuda Kazuko | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 149,625 | 0.00 | — | 149,625 | — | ↗ |
| 2023-01-23 | IWAKI YUICHI | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 235,125 | 0.00 | — | 235,125 | — | ↗ |
| 2022-11-28 | Nagao Hideki | Director | S-Sale | D | Common Stock | 6,754 | 2.25 | 15.2K | 0 | — | ↗ |
| 2022-11-22 | Nagao Hideki | Director | S-Sale | D | Common Stock | 218 | 2.13 | 464.34 | 6,754 | — | ↗ |
| 2022-11-21 | Nagao Hideki | Director | S-Sale | D | Common Stock | 5,365 | 2.18 | 11.7K | 6,972 | — | ↗ |
| 2022-11-17 | Nagao Hideki | Director | S-Sale | D | Common Stock | 309 | 2.18 | 673.62 | 12,337 | — | ↗ |
| 2022-06-16 | Nagao Hideki | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-06-16 | Kruger Jason J | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-06-16 | BEAVER CAROLYN | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 2.51 | 50.2K | 20,000 | — | ↗ |
| 2022-01-27 | OBrien Geoffrey | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 99,000 | 5.92 | 586.1K | 99,000 | — | ↗ |
| 2022-01-27 | Matsuda Kazuko | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 192,500 | 5.92 | 1.14M | 192,500 | — | ↗ |
| 2022-01-27 | IWAKI YUICHI | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 302,500 | 5.92 | 1.79M | 302,500 | — | ↗ |
| 2021-08-23 | Matsuda Kazuko | Director / Officer | M-Exempt | A | Common Stock | 60,000 | 2.30 | 138.0K | 322,996 | — | ↗ |
| 2021-08-01 | Paulin Douglas | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-07-09 | IWAKI YUICHI | Director / Officer | M-Exempt | D | Employee Stock option (Right to Buy) | 39,583 | 2.54 | 100.5K | 0 | — | ↗ |
| 2021-06-24 | Matsuda Kazuko | Director / Officer | M-Exempt | A | Common Stock | 56,250 | 2.46 | 138.4K | 262,996 | — | ↗ |
| 2021-06-16 | Nagao Hideki | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 3.95 | 79.0K | 20,000 | — | ↗ |
| 2021-06-16 | BEAVER CAROLYN | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 3.95 | 79.0K | 20,000 | — | ↗ |
| 2021-05-19 | OBrien Geoffrey | Officer | M-Exempt | A | Common Stock | 11,318 | 2.46 | 27.8K | 48,318 | — | ↗ |
| 2021-04-22 | Gaeta Federico C.A. | Officer | — | D | Employee Stock Option (Right to Buy) | 20,000 | 5.42 | 108.4K | 0 | — | ↗ |
| 2021-03-11 | Nagao Hideki | Director | S-Sale | D | Common Stock | 2,354 | 7.40 | 17.4K | 12,646 | — | ↗ |
| 2021-02-25 | IWAKI YUICHI | Director / Officer | M-Exempt | A | Common Stock | 86,250 | 2.46 | 212.2K | 927,350 | — | ↗ |
| 2021-02-02 | OBrien Geoffrey | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 99,000 | 6.89 | 682.1K | 99,000 | — | ↗ |
| 2021-02-02 | Matsuda Kazuko | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 325,000 | 6.89 | 2.24M | 325,000 | — | ↗ |
| 2021-02-02 | IWAKI YUICHI | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 495,000 | 6.89 | 3.41M | 495,000 | — | ↗ |
| 2021-01-11 | 3D Investment Partners Pte. Ltd. | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 5,502,047 | — | ↗ |
| 2020-10-20 | BEAVER CAROLYN | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 5.40 | 81.0K | 15,000 | — | ↗ |
| 2020-09-15 | Nagao Hideki | Director | S-Sale | D | Common Stock | 1,000 | 5.78 | 5.8K | 15,000 | — | ↗ |
| 2020-08-06 | Nagao Hideki | Director | M-Exempt | A | Common Stock | 15,000 | 2.58 | 38.7K | 16,000 | — | ↗ |
| 2020-06-19 | Stepanow Edward C Jr. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-06-16 | Nagao Hideki | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 5.70 | 114.0K | 20,000 | — | ↗ |
| 2020-06-16 | Kobayashi Yutaka | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 5.70 | 114.0K | 20,000 | — | ↗ |
| 2020-06-12 | Matsuda Kazuko | Director / Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 20,000 | 5.13 | 102.6K | 0 | — | ↗ |
| 2020-04-08 | Matsuda Kazuko | Director / Officer | M-Exempt | A | Common Stock | 28,446 | 2.54 | 72.3K | 140,192 | — | ↗ |
| 2020-04-08 | IWAKI YUICHI | Director / Officer | M-Exempt | A | Common Stock | 60,417 | 2.54 | 153.5K | 841,100 | — | ↗ |
| 2020-03-13 | Matsuda Kazuko | Director / Officer | P-Purchase | A | Common Stock | 2,000 | 3.62 | 7.2K | 111,746 | — | ↗ |
| 2020-03-12 | IWAKI YUICHI | Director / Officer | P-Purchase | A | Common Stock | 20,000 | 3.10 | 62.0K | 780,683 | — | ↗ |
| 2020-01-09 | OBrien Geoffrey | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 165,000 | 9.67 | 1.60M | 165,000 | — | ↗ |
| 2020-01-09 | Matsuda Kazuko | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 243,750 | 9.67 | 2.36M | 243,750 | — | ↗ |
| 2020-01-09 | IWAKI YUICHI | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 412,500 | 9.67 | 3.99M | 412,500 | — | ↗ |
| 2019-06-12 | Matsuda Kazuko | Officer | M-Exempt | A | Common Stock | 37,000 | 4.80 | 177.6K | 109,457 | — | ↗ |
| 2019-06-10 | Nagao Hideki | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 9.58 | 191.6K | 20,000 | — | ↗ |
| 2019-06-10 | Kobayashi Yutaka | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 9.58 | 191.6K | 20,000 | — | ↗ |
| 2019-06-10 | Ishizaka Yoshio | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 9.58 | 191.6K | 20,000 | — | ↗ |
| 2019-05-13 | Nagao Hideki | Director | M-Exempt | D | Employee Stock Option (Right to Buy) | 1,000 | 2.77 | 2.8K | 0 | — | ↗ |
| 2019-02-28 | Okajima Masatsune | Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 35,700 | 7.34 | 262.0K | 0 | — | ↗ |
| 2019-01-15 | Okajima Masatsune | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 105,000 | 7.00 | 735.0K | 105,000 | — | ↗ |
| 2019-01-15 | OBrien Geoffrey | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 205,000 | 7.00 | 1.44M | 205,000 | — | ↗ |
| 2019-01-15 | Matsuda Kazuko | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 295,000 | 7.00 | 2.07M | 295,000 | — | ↗ |
| 2019-01-15 | IWAKI YUICHI | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 470,000 | 7.00 | 3.29M | 470,000 | — | ↗ |
| 2019-01-09 | Okajima Masatsune | Officer | M-Exempt | A | Common Stock | 41,250 | 2.20 | 90.8K | 153,580 | — | ↗ |
| 2019-01-03 | IWAKI YUICHI | Director / Officer | M-Exempt | A | Common Stock | 18,572 | 2.20 | 40.9K | 759,392 | — | ↗ |
| 2018-06-07 | Nagao Hideki | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 9.34 | 186.8K | 20,000 | — | ↗ |
| 2018-06-07 | Kobayashi Yutaka | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 9.34 | 186.8K | 20,000 | — | ↗ |
| 2018-06-07 | Ishizaka Yoshio | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 9.34 | 186.8K | 20,000 | — | ↗ |
| 2018-06-01 | Reyes Carla | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-03-05 | IWAKI YUICHI | Director / Officer | M-Exempt | A | Common Stock | 50,003 | 2.20 | 110.0K | 740,594 | — | ↗ |
| 2018-01-06 | Okajima Masatsune | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 100,000 | 6.10 | 610.0K | 100,000 | — | ↗ |
| 2018-01-06 | OBrien Geoffrey | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 200,000 | 6.10 | 1.22M | 200,000 | — | ↗ |
| 2018-01-06 | Matsuda Kazuko | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 280,000 | 6.10 | 1.71M | 280,000 | — | ↗ |
| 2018-01-06 | IWAKI YUICHI | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 450,000 | 6.10 | 2.75M | 450,000 | — | ↗ |
| 2018-01-03 | IWAKI YUICHI | Director / Officer | M-Exempt | A | Common Stock | 53,363 | 4.42 | 235.9K | 690,591 | — | ↗ |
| 2017-12-12 | Okajima Masatsune | Officer | M-Exempt | A | Common Stock | 48,000 | 4.42 | 212.2K | 108,941 | — | ↗ |
| 2017-11-09 | Nagao Hideki | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 6.51 | 130.2K | 20,000 | — | ↗ |
| 2017-11-02 | IWAKI YUICHI | Director / Officer | M-Exempt | A | Common Stock | 21,067 | 4.42 | 93.1K | 637,228 | — | ↗ |
| 2017-08-21 | Ishizaka Yoshio | Director | P-Purchase | A | Common Stock | 5,000 | 5.17 | 25.9K | 10,000 | — | ↗ |
| 2017-06-08 | Kobayashi Yutaka | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 5.65 | 113.0K | 20,000 | — | ↗ |
| 2017-06-08 | Ishizaka Yoshio | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 5.65 | 113.0K | 20,000 | — | ↗ |
| 2017-05-15 | Kobayashi Yutaka | Director | P-Purchase | A | Common Stock | 1,000 | 5.60 | 5.6K | 25,000 | — | ↗ |
| 2017-05-12 | Kobayashi Yutaka | Director | P-Purchase | A | Common Stock | 24,000 | 5.62 | 134.9K | 24,000 | — | ↗ |
| 2017-01-18 | Okajima Masatsune | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 120,000 | 3.91 | 469.2K | 120,000 | — | ↗ |
| 2017-01-18 | OBrien Geoffrey | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 115,000 | 3.91 | 449.7K | 115,000 | — | ↗ |
| 2017-01-18 | Matsuda Kazuko | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 170,000 | 3.91 | 664.7K | 170,000 | — | ↗ |
| 2017-01-18 | IWAKI YUICHI | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 320,000 | 3.91 | 1.25M | 320,000 | — | ↗ |
| 2016-09-15 | Kobayashi Yutaka | Director | P-Purchase | A | Common Stock | 11,800 | 6.44 | 76.0K | 81,800 | — | ↗ |
| 2016-09-09 | Kobayashi Yutaka | Director | P-Purchase | A | Common Stock | 10,000 | 6.67 | 66.7K | 70,000 | — | ↗ |
| 2016-07-05 | OBrien Geoffrey | Officer | M-Exempt | A | Common Stock | 3,300 | 4.80 | 15.8K | 8,300 | — | ↗ |
| 2016-06-09 | Kobayashi Yutaka | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 6.64 | 132.8K | 20,000 | — | ↗ |
| 2016-06-09 | Ishizaka Yoshio | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 6.64 | 132.8K | 20,000 | — | ↗ |
| 2016-03-31 | Selhorn Ryan J | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-03-14 | Okajima Masatsune | Officer | X-InTheMoney | A | Common Stock | 8,400 | 3.56 | 29.9K | 51,138 | — | ↗ |
| 2016-03-14 | Matsuda Kazuko | Officer | X-InTheMoney | A | Common Stock | 800 | 3.56 | 2.8K | 62,003 | — | ↗ |
| 2016-01-20 | Okajima Masatsune | Officer | P-Purchase | A | Warrants (Right to Buy) | 8,400 | 3.56 | 29.9K | 8,400 | — | ↗ |
| 2016-01-20 | Matsuda Kazuko | Officer | S-Sale | D | Warrants (Right to Buy) | 8,400 | 3.56 | 29.9K | 800 | — | ↗ |
| 2016-01-07 | Okajima Masatsune | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 105,000 | 3.09 | 324.5K | 105,000 | — | ↗ |
| 2016-01-07 | OBrien Geoffrey | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 105,000 | 3.09 | 324.5K | 105,000 | — | ↗ |
| 2016-01-07 | Matsuda Kazuko | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 125,000 | 3.09 | 386.3K | 125,000 | — | ↗ |
| 2016-01-07 | IWAKI YUICHI | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 120,000 | 3.89 | 466.8K | 120,000 | — | ↗ |
| 2015-07-09 | Kobayashi Yutaka | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 3.96 | 79.2K | 20,000 | — | ↗ |
| 2015-07-09 | Ishizaka Yoshio | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 3.96 | 79.2K | 20,000 | — | ↗ |
| 2014-12-10 | Kobayashi Yutaka | Director | P-Purchase | A | Common Stock | 12,000 | 3.54 | 42.5K | 60,000 | — | ↗ |
| 2014-12-04 | Okajima Masatsune | Officer | A-Award | A | Employee Stock option (right to buy) | 15,000 | 3.24 | 48.6K | 15,000 | — | ↗ |
| 2014-12-04 | OBrien Geoffrey | Officer | A-Award | A | Employee Stock option (right to buy) | 15,000 | 3.24 | 48.6K | 15,000 | — | ↗ |
| 2014-12-04 | Matsuda Kazuko | Officer | A-Award | A | Employee Stock option (right to buy) | 105,000 | 2.64 | 277.2K | 105,000 | — | ↗ |
| 2014-12-04 | IWAKI YUICHI | Director / Officer | A-Award | A | Employee Stock option (right to buy) | 200,000 | 2.64 | 528.0K | 200,000 | — | ↗ |
| 2014-11-26 | Kobayashi Yutaka | Director | P-Purchase | A | Common Stock | 10,000 | 3.07 | 30.7K | 48,000 | — | ↗ |
| 2014-11-20 | Kobayashi Yutaka | Director | P-Purchase | A | Common Stock | 13,000 | 3.19 | 41.5K | 38,000 | — | ↗ |
| 2014-11-19 | Ishizaka Yoshio | Director | P-Purchase | A | Common Stock | 5,000 | 2.86 | 14.3K | 5,000 | — | ↗ |
| 2014-09-11 | Kobayashi Yutaka | Director | P-Purchase | A | Common Stock | 10,000 | 2.95 | 29.5K | 25,000 | — | ↗ |
| 2014-09-03 | Kobayashi Yutaka | Director | P-Purchase | A | Common Stock | 9,900 | 2.67 | 26.4K | 15,000 | — | ↗ |
| 2014-08-07 | van den Boom Esther | Officer | A-Award | A | Stock Option (Right to Buy) | 10,000 | 2.00 | 20.0K | 10,000 | — | ↗ |
| 2014-04-08 | van den Boom Esther | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2014-04-08 | Ishizaka Yoshio | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.05 | 30.8K | 15,000 | — | ↗ |
| 2013-12-12 | Izumi Tatsuo | Director | S-Sale | D | Common Stock | 70,300 | 2.10 | 147.8K | 600,970 | — | ↗ |
| 2013-12-02 | Okajima Masatsune | Officer | A-Award | A | Employee Stock Option (right to buy) | 80,000 | 4.10 | 328.0K | 80,000 | — | ↗ |
| 2013-12-02 | OBrien Geoffrey | Officer | A-Award | A | Employee Stock Option (right to buy) | 55,000 | 4.10 | 225.5K | 55,000 | — | ↗ |
| 2013-12-02 | Matsuda Kazuko | Officer | A-Award | A | Employee Stock Option (right to buy) | 80,000 | 4.10 | 328.0K | 80,000 | — | ↗ |
| 2013-12-02 | IWAKI YUICHI | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 145,000 | 4.10 | 594.5K | 145,000 | — | ↗ |
| 2013-11-18 | Izumi Tatsuo | Director | P-Purchase | A | Common Stock | 300 | 2.23 | 668.70 | 670,300 | — | ↗ |
| 2013-10-15 | OBrien Geoffrey | Officer | — | D | Employee Stock Option (right to buy) | 25,000 | 4.80 | 120.0K | 0 | — | ↗ |
| 2013-10-15 | Nagao Hideki | Director | — | D | Stock Option (right to buy) | 15,000 | 2.58 | 38.7K | 0 | — | ↗ |
| 2013-10-15 | Kobayashi Yutaka | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 2.58 | 38.7K | 15,000 | — | ↗ |
| 2013-05-21 | Morris Arlene | Director | M-Exempt | D | Stock Option (Right to Buy) | 7,800 | 2.40 | 18.7K | 36,200 | — | ↗ |
| 2013-05-13 | Satomi Hajime | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 1,000,000 | — | ↗ |
| 2013-05-13 | Okajima Masatsune | Officer | A-Award | A | Stock Option (Right to Buy) | 42,500 | 4.10 | 174.3K | 42,500 | — | ↗ |
| 2013-05-13 | Matsuda Kazuko | Officer | A-Award | A | Stock Option (Right to Buy) | 42,500 | 4.10 | 174.3K | 42,500 | — | ↗ |
| 2013-05-13 | Johnson Kirk William | Officer | A-Award | A | Stock Option (Right to Buy) | 42,500 | 4.10 | 174.3K | 42,500 | — | ↗ |
| 2013-05-13 | Izumi Tatsuo | Director | P-Purchase | A | Warrant to Purchase Common Stock | 119,047 | 3.15 | 375.0K | 119,047 | — | ↗ |
| 2013-05-13 | IWAKI YUICHI | Officer | A-Award | A | Stock Option (Right to Buy) | 62,500 | 4.10 | 256.3K | 62,500 | — | ↗ |
| 2013-05-13 | COFFEE MICHAEL DENIS | Officer | A-Award | A | Stock Option (Right to Buy) | 42,500 | 4.10 | 174.3K | 42,500 | — | ↗ |
| 2012-06-14 | Okajima Masatsune | Officer | A-Award | A | Stock Option (Right to Buy) | 63,750 | 2.46 | 156.8K | 63,750 | — | ↗ |
| 2012-06-14 | OBrien Geoffrey | Officer | — | D | Employee Stock Option (right to buy) | 26,250 | 2.46 | 64.6K | 0 | — | ↗ |
| 2012-06-14 | Matsuda Kazuko | Officer | A-Award | A | Stock Option (Right to Buy) | 56,250 | 2.46 | 138.4K | 56,250 | — | ↗ |
| 2012-06-14 | Johnson Kirk William | Officer | A-Award | A | Stock Option (Right to Buy) | 63,750 | 2.46 | 156.8K | 63,750 | — | ↗ |
| 2012-06-14 | IWAKI YUICHI | Officer | A-Award | A | Stock Option (Right to Buy) | 86,250 | 2.46 | 212.2K | 86,250 | — | ↗ |
| 2012-06-14 | COFFEE MICHAEL DENIS | Officer | A-Award | A | Stock Option (Right to Buy) | 63,750 | 2.46 | 156.8K | 63,750 | — | ↗ |
| 2012-05-31 | Izumi Tatsuo | Director | P-Purchase | A | Common Stock | 5,200 | 1.81 | 9.4K | 56,800 | — | ↗ |
| 2012-05-29 | O'Toole David D | Director | P-Purchase | A | Common Stock | 5,000 | 1.78 | 8.9K | 5,000 | — | ↗ |
| 2012-05-29 | Izumi Tatsuo | Director | P-Purchase | A | Common Stock | 6,600 | 1.98 | 13.1K | 51,600 | — | ↗ |
| 2012-05-28 | Izumi Tatsuo | Director | P-Purchase | A | Common Stock | 30,000 | 1.94 | 58.2K | 45,000 | — | ↗ |
| 2012-05-10 | Shigeta Hiroaki | Director | M-Exempt | D | Stock Option (Right to Buy) | 1,000 | 2.28 | 2.3K | 0 | — | ↗ |
| 2012-04-10 | O'Toole David D | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 2.59 | 38.9K | 15,000 | — | ↗ |
| 2012-04-04 | Izumi Tatsuo | Director | M-Exempt | A | Common Stock | 15,000 | 1.99 | 29.9K | 15,000 | — | ↗ |
| 2011-11-29 | Nakata Kousuke | Director | — | I | Common Stock, $0.001 par value | 0 | 0.00 | — | 800,000 | — | ↗ |
| 2011-10-13 | Kissei Pharmaceutical Co., Ltd. | 10% Owner | — | D | Common Stock ($0.001 par value) | 0 | 0.00 | — | 800,000 | — | ↗ |
| 2011-09-25 | Izumi Tatsuo | Director | — | D | Common Stock | 0 | 0.00 | — | 613,200 | — | ↗ |
| 2011-09-01 | Matsuda Kazuko | Officer | — | D | Options to Purchase Common Stock (Right to Buy) | 20,000 | 5.13 | 102.6K | 0 | — | ↗ |
| 2011-09-01 | Gennaro Michael J | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2011-07-18 | Shigeta Hiroaki | Director | A-Award | A | Stock Option (Right to Buy) | 14,000 | 2.40 | 33.6K | 14,000 | — | ↗ |
| 2011-07-18 | PRENDERGAST JOHN K A | Director | A-Award | A | Stock Option (Right to Buy) | 14,000 | 2.40 | 33.6K | 14,000 | — | ↗ |
| 2011-07-18 | Morris Arlene | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 2.40 | 72.0K | 30,000 | — | ↗ |
| 2011-07-13 | IWAKI YUICHI | Director / Officer | A-Award | A | Employee Stock option (Right to Buy) | 100,000 | 2.54 | 254.0K | 100,000 | — | ↗ |
| 2011-06-14 | Shigeta Hiroaki | Director | A-Award | A | Stock Option (Right to Buy) | 1,000 | 2.28 | 2.3K | 1,000 | — | ↗ |
| 2011-06-14 | PRENDERGAST JOHN K A | Director | A-Award | A | Stock Option (Right to Buy) | 1,000 | 2.28 | 2.3K | 1,000 | — | ↗ |
| 2011-06-14 | Morris Arlene | Director | A-Award | A | Stock Option (Right to Buy) | 1,000 | 2.28 | 2.3K | 1,000 | — | ↗ |
| 2011-06-14 | Himawan Jeff | Director | A-Award | A | Stock Option (Right to Buy) | 1,000 | 2.28 | 2.3K | 1,000 | — | ↗ |
| 2011-03-29 | OBrien Geoffrey | Officer | — | D | Warrant (right to buy) | 5,000 | 3.56 | 17.8K | 0 | — | ↗ |
| 2011-03-29 | Matsuda Kazuko | Officer | — | D | Common Stock Warrant (Right to Buy) | 9,200 | 3.56 | 32.8K | 0 | — | ↗ |
| 2011-03-29 | Johnson Kirk William | Officer | P-Purchase | A | Common Stock Warrants (Right to Buy) | 2,200 | 3.56 | 7.8K | 2,200 | — | ↗ |
| 2011-03-29 | IWAKI YUICHI | Director / Officer | P-Purchase | A | Common Stock Warrants (Right to Buy) | 50,000 | 3.56 | 178.0K | 50,000 | — | ↗ |
| 2011-03-29 | COFFEE MICHAEL DENIS | Officer | P-Purchase | A | Common Stock Warrants (Right to Buy) | 4,000 | 3.56 | 14.2K | 4,000 | — | ↗ |
| 2010-06-14 | COFFEE MICHAEL DENIS | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 5.13 | 513.0K | 100,000 | — | ↗ |
| 2010-06-11 | Shigeta Hiroaki | Director | A-Award | A | Stock Option (right to buy) | 1,000 | 5.13 | 5.1K | 1,000 | — | ↗ |
| 2010-06-11 | PRENDERGAST JOHN K A | Director | A-Award | A | Stock Option (right to buy) | 1,000 | 5.13 | 5.1K | 1,000 | — | ↗ |
| 2010-06-11 | Morris Arlene | Director | A-Award | A | Stock Option (right to buy) | 1,000 | 5.13 | 5.1K | 1,000 | — | ↗ |
| 2010-06-11 | Himawan Jeff | Director | A-Award | A | Stock Option (right to buy) | 1,000 | 5.13 | 5.1K | 1,000 | — | ↗ |
| 2010-06-11 | DUNTON ALAN W | Director | A-Award | A | Stock Option (right to buy) | 1,000 | 5.13 | 5.1K | 1,000 | — | ↗ |
| 2010-02-01 | Johnson Kirk William | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 7.34 | 734.0K | 100,000 | — | ↗ |
| 2010-01-29 | Okajima Masatsune | Officer | A-Award | A | Stock Option (right to buy) | 35,700 | 7.34 | 262.0K | 35,700 | — | ↗ |
| 2010-01-29 | IWAKI YUICHI | Director / Officer | A-Award | A | Stock Option (right to buy) | 58,600 | 7.34 | 430.1K | 58,600 | — | ↗ |
| 2010-01-29 | Asako Shintaro | Officer | A-Award | A | Stock Option (right to buy) | 35,700 | 7.34 | 262.0K | 35,700 | — | ↗ |
| 2009-12-18 | BVF PARTNERS L P/IL | 10% Owner | — | I | Secured Convertible Note | 821,233 | 6.80 | 5.58M | 0 | — | ↗ |
| 2009-12-12 | Nagao Hideki | Director | — | D | Stock Option (right to buy) | 1,000 | 2.77 | 2.8K | 0 | — | ↗ |
| 2009-09-14 | Shigeta Hiroaki | Director | A-Award | A | Stock Option (right to buy) | 1,000 | 6.18 | 6.2K | 1,000 | — | ↗ |
| 2009-07-28 | Kalafer Michael E | Officer | P-Purchase | A | Common Stock | 19,586 | 4.42 | 86.6K | 31,744 | — | ↗ |
| 2009-06-12 | PRENDERGAST JOHN K A | Director | A-Award | A | Stock Option (right to buy) | 1,000 | 2.77 | 2.8K | 1,000 | — | ↗ |
| 2009-06-12 | Nagao Hideki | Director | A-Award | A | Stock Option (right to buy) | 1,000 | 2.77 | 2.8K | 1,000 | — | ↗ |
| 2009-06-12 | Morris Arlene | Director | A-Award | A | Stock Option (right to buy) | 1,000 | 2.77 | 2.8K | 1,000 | — | ↗ |
| 2009-06-12 | Himawan Jeff | Director | A-Award | A | Stock Option (right to buy) | 1,000 | 2.77 | 2.8K | 1,000 | — | ↗ |
| 2009-06-12 | DUNTON ALAN W | Director | A-Award | A | Stock Option (right to buy) | 1,000 | 2.77 | 2.8K | 1,000 | — | ↗ |
| 2009-02-02 | IWAKI YUICHI | Director / Officer | P-Purchase | A | Common Stock, par value $0.001 | 1,800 | 2.25 | 4.1K | 643,972 | — | ↗ |
| 2009-01-30 | Okajima Masatsune | Officer | A-Award | A | Stock Option (right to buy) | 41,250 | 2.20 | 90.8K | 41,250 | — | ↗ |
| 2009-01-30 | Kalafer Michael E | Officer | A-Award | A | Stock Option (right to buy) | 41,250 | 2.20 | 90.8K | 41,250 | — | ↗ |
| 2009-01-30 | IWAKI YUICHI | Director / Officer | A-Award | A | Stock Option (right to buy) | 97,500 | 2.20 | 214.5K | 97,500 | — | ↗ |
| 2009-01-30 | GAMMANS RICHARD E SR | Officer | A-Award | A | Stock Option (right to buy) | 60,000 | 2.20 | 132.0K | 60,000 | — | ↗ |
| 2009-01-30 | Asako Shintaro | Officer | A-Award | A | Stock Option (right to buy) | 60,000 | 2.20 | 132.0K | 60,000 | — | ↗ |
| 2009-01-27 | IWAKI YUICHI | Director / Officer | P-Purchase | A | Common Stock, par vlaue $0.001 | 1,200 | 2.19 | 2.6K | 642,172 | — | ↗ |
| 2009-01-26 | IWAKI YUICHI | Director / Officer | P-Purchase | A | Common Stock, par value $0.001 | 1,650 | 2.15 | 3.5K | 640,972 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-9.2K
Shares Outstanding
49.22M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Yuichi Iwaki, M.D., Ph.D. President and Chief Executive Officer | 657.4K | — | — | 729.6K | 328.7K | 21.0K | 1.74M | 42.01% | ↗ |
| 2 | 2025 | Kazuko Matsuda, M.D., Ph.D., MPH Senior Vice President, Chief Medical Officer | 514.4K | — | — | 589.9K | 205.8K | 21.0K | 1.33M | 44.32% | ↗ |
| 3 | 2025 | David H. Crean, Ph.D. Chief Business Officer | 120.0K | — | — | — | — | — | 120.0K | 0.00% | ↗ |
| 4 | 2024 | Yuichi Iwaki, M.D., Ph.D. President and Chief Executive Officer | 657.4K | — | — | 401.5K | 328.7K | 20.7K | 1.41M | 28.51% | ↗ |
| 5 | 2024 | Kazuko Matsuda, M.D., Ph.D., MPH Senior Vice President, Chief Medical Officer | 505.4K | — | — | 301.1K | 176.9K | 20.7K | 1.00M | 29.99% | ↗ |
| 6 | 2024 | Kazuko Matsuda, M.D., Ph.D., MPH Chief Medical Officer | 505.4K | — | — | 301.1K | 176.9K | 20.7K | 1.00M | 29.99% | ↗ |
| 7 | 2024 | Geoffrey O’Brien, J.D./M.B.A. Former Vice President | 155.8K | — | — | — | — | 14.9K | 170.7K | 0.00% | ↗ |
| 8 | 2024 | David H. Crean, Ph.D. Chief Business Officer | 99.0K | — | — | — | — | — | 99.0K | 0.00% | ↗ |
| 9 | 2023 | Yuichi Iwaki, M.D., Ph.D. President and Chief Executive Officer | 657.4K | — | — | 481.1K | 230.1K | 19.8K | 1.39M | 34.65% | ↗ |
| 10 | 2023 | Kazuko Matsuda, M.D., Ph.D. Chief Medical Officer | 505.4K | — | — | 360.8K | 123.8K | 19.8K | 1.01M | 35.73% | ↗ |
| 11 | 2023 | Kazuko Matsuda, M.D., Ph.D., MPH Chief Medical Officer | 505.4K | — | — | 360.8K | 123.8K | 19.8K | 1.01M | 35.73% | ↗ |
| 12 | 2023 | Geoffrey O’Brien, J.D./M.B.A. Former Vice President | 378.6K | — | — | 192.4K | 92.7K | 19.8K | 683.5K | 28.15% | ↗ |
| 13 | 2023 | Geoffrey O’Brien, J.D./M.B.A. Vice President | 378.6K | — | — | 192.4K | 92.7K | 19.8K | 683.5K | 28.15% | ↗ |
| 14 | 2022 | Yuichi Iwaki, M.D., Ph.D. President and Chief Executive Officer | 620.2K | — | — | 359.6K | 294.6K | 18.3K | 1.29M | 27.82% | ↗ |
| 15 | 2022 | Kazuko Matsuda, M.D., Ph.D. Chief Medical Officer | 476.8K | — | — | 228.8K | 158.5K | 18.3K | 882.5K | 25.93% | ↗ |
| 16 | 2022 | Geoffrey O’Brien, J.D./M.B.A. Vice President | 357.2K | — | — | 117.7K | 118.8K | 18.3K | 611.9K | 19.23% | ↗ |
| 17 | 2021 | Yuichi Iwaki, M.D., Ph.D. President and Chief Executive Officer | 596.3K | — | — | 1.98M | 164.0K | 17.4K | 2.76M | 71.80% | ↗ |
| 18 | 2021 | Kazuko Matsuda, M.D., Ph.D. Chief Medical Officer | 458.5K | — | — | 1.26M | 88.3K | 17.4K | 1.82M | 69.08% | ↗ |
| 19 | 2021 | Geoffrey O’Brien, J.D./M.B.A. Vice President | 343.4K | — | — | 648.1K | 66.1K | 17.4K | 1.08M | 60.29% | ↗ |
| 20 | 2020 | Yuichi Iwaki, M.D., Ph.D. President and Chief Executive Officer | 586.9K | — | — | 2.10M | 264.1K | 17.1K | 2.97M | 70.73% | ↗ |
| 21 | 2020 | Kazuko Matsuda, M.D., Ph.D. Chief Medical Officer | 451.3K | — | — | 1.24M | 157.9K | 17.1K | 1.87M | 66.44% | ↗ |
| 22 | 2020 | Geoffrey O’Brien, J.D./M.B.A. Vice President | 338.0K | — | — | 839.2K | 53.2K | 17.1K | 1.25M | 67.27% | ↗ |
| 23 | 2019 | Yuichi Iwaki, M.D., Ph.D. President and Chief and Executive Officer | 572.1K | — | — | 2.96M | 214.5K | 16.8K | 3.76M | 78.64% | ↗ |
| 24 | 2019 | Yuichi Iwaki, M.D., Ph.D. President and Chief Executive Officer | 572.1K | — | — | 2.96M | 214.5K | 16.8K | 3.76M | 78.64% | ↗ |
| 25 | 2019 | Kazuko Matsuda, M.D., Ph.D. Chief Medical Officer | 439.8K | — | — | 1.75M | 131.9K | 16.8K | 2.34M | 74.81% | ↗ |
| 26 | 2019 | Geoffrey O’Brien, J.D./M.B.A. Vice President | 329.4K | — | — | 1.18M | 98.8K | 16.8K | 1.63M | 72.67% | ↗ |
| 27 | 2018 | Yuichi Iwaki, M.D., Ph.D. President and Chief Executive Officer | 551.1K | — | — | 1.91M | 372.0K | 16.5K | 2.85M | 67.07% | ↗ |
| 28 | 2018 | Yuichi Iwaki, M.D., Ph.D. President and Chief and Executive Officer | 551.1K | — | — | 1.91M | 372.0K | 16.5K | 2.85M | 67.07% | ↗ |
| 29 | 2018 | Kazuko Matsuda, M.D., Ph.D. Chief Medical Officer | 394.8K | — | — | 1.20M | 213.2K | 16.5K | 1.83M | 65.79% | ↗ |
| 30 | 2018 | Geoffrey O’Brien, J.D./M.B.A. Vice President | 307.7K | — | — | 834.7K | 166.2K | 16.5K | 1.33M | 62.99% | ↗ |
| 31 | 2017 | Yuichi Iwaki, M.D., Ph.D. President and Chief and Executive Officer | 533.5K | — | — | 1.74M | 266.8K | 16.2K | 1.94M | 89.91% | ↗ |
| 32 | 2017 | Kazuko Matsuda, M.D., Ph.D. Chief Medical Officer | 382.2K | — | — | 1.08M | 172.0K | 8.3K | 1.65M | 65.82% | ↗ |
| 33 | 2017 | Geoffrey O’Brien, J.D./M.B.A. Vice President | 297.9K | — | — | 773.7K | 128.1K | 16.2K | 1.22M | 63.63% | ↗ |
| 34 | 2017 | Masatsune Okajima Vice President and Head of Japanese Office | 310.3K | — | — | 386.9K | 77.6K | 14.7K | 789.4K | 49.01% | ↗ |
| 35 | 2017 | Ryan Selhorn, CPA Chief Financial Officer | 132.3K | — | — | — | — | — | 132.3K | 0.00% | ↗ |
| 36 | 2016 | Yuichi Iwaki, M.D., Ph.D. President and Chief and Executive Officer | 523.0K | — | — | 1.14M | 261.5K | 15.9K | 1.94M | 58.66% | ↗ |
| 37 | 2016 | Kazuko Matsuda, M.D., Ph.D. Chief Medical Officer | 347.5K | — | — | 697.8K | 121.6K | 8.5K | 1.18M | 59.37% | ↗ |
| 38 | 2016 | Masatsune Okajima Vice President and Head of Japanese Office | 304.2K | — | — | 386.9K | 106.5K | 18.4K | 815.9K | 47.42% | ↗ |
| 39 | 2016 | Geoffrey O’Brien, J.D./M.B.A. Vice President | 259.1K | — | — | 374.0K | 90.7K | 15.9K | 739.6K | 50.57% | ↗ |
| 40 | 2016 | Ryan Selhorn, CPA Chief Financial Officer | 58.8K | — | — | — | — | — | 58.8K | 0.00% | ↗ |
| 41 | 2016 | Esther van den Boom, CPA Former Chief Financial Officer | 37.0K | — | — | — | — | — | 37.0K | 0.00% | ↗ |
| 42 | 2015 | Yuichi Iwaki, M.D., Ph.D. President and Chief and Executive Officer | 518.9K | — | — | 510.9K | 259.4K | 15.9K | 1.31M | 39.14% | ↗ |
| 43 | 2015 | Kazuko Matsuda, M.D., Ph.D. Chief Medical Officer | 344.7K | — | — | 255.4K | 120.6K | 9.1K | 729.9K | 35.00% | ↗ |
| 44 | 2015 | Masatsune Okajima Vice President and Head of Japanese Office | 301.8K | — | — | 214.6K | 105.6K | 15.9K | 637.8K | 33.64% | ↗ |
| 45 | 2015 | Geoffrey O’Brien, J.D./M.B.A. Vice President | 257.0K | — | — | 214.6K | 90.0K | 15.9K | 577.4K | 37.16% | ↗ |
| 46 | 2015 | Esther van den Boom, CPA Former Chief Financial Officer | 95.1K | — | — | — | — | — | 95.1K | 0.00% | ↗ |
| 47 | 2014 | Yuichi Iwaki, M.D., Ph.D. President and Chief and Executive Officer | 504.8K | — | — | — | 252.4K | 12.0K | 769.1K | 0.00% | ↗ |
| 48 | 2014 | Yuichi Iwaki, M.D., Ph.D. President and Chief and Executive Officer | 504.8K | — | — | — | 252.4K | 12.0K | 769.1K | 0.00% | ↗ |
| 49 | 2014 | Kazuko Matsuda, M.D., Ph.D. Chief Medical Officer | 293.6K | — | — | — | 102.7K | 15.6K | 682.8K | 0.00% | ↗ |
| 50 | 2014 | Kazuko Matsuda, M.D., Ph.D. Chief Medical Officer | 293.6K | — | — | 270.9K | 102.7K | 15.6K | 682.8K | 39.68% | ↗ |
| 51 | 2014 | Masatsune Okajima Vice President and Head of Japanese Office | 293.6K | — | — | — | 102.7K | 17.5K | 447.7K | 0.00% | ↗ |
| 52 | 2014 | Masatsune Okajima Vice President and Head of Japanese Office | 293.6K | — | — | 33.9K | 102.7K | 17.5K | 447.7K | 7.56% | ↗ |
| 53 | 2013 | Yuichi Iwaki, M.D., Ph.D. President and Chief and Executive Officer | 504.8K | — | — | 957.1K | 138.8K | 14.7K | 1.62M | 59.25% | ↗ |
| 54 | 2013 | Yuichi Iwaki, M.D., Ph.D. President and Chief and Executive Officer | 504.8K | — | — | — | 138.8K | 14.7K | 1.62M | 0.00% | ↗ |
| 55 | 2013 | Kazuko Matsuda, M.D., Ph.D. Chief Medical Officer | 293.6K | — | — | — | 56.5K | 23.8K | 915.0K | 0.00% | ↗ |
| 56 | 2013 | Kazuko Matsuda, M.D., Ph.D. Chief Medical Officer | 293.6K | — | — | 541.2K | 56.5K | 23.8K | 915.0K | 59.14% | ↗ |
| 57 | 2013 | Masatsune Okajima Vice President and Head of Japanese Office | 293.6K | — | — | 541.2K | 56.5K | 18.4K | 909.6K | 59.49% | ↗ |
| 58 | 2013 | Masatsune Okajima Vice President and Head of Japanese Office | 293.6K | — | — | — | 56.5K | 18.4K | 909.6K | 0.00% | ↗ |
| 59 | 2012 | Yuichi Iwaki, M.D., Ph.D. President and Chief and Executive Officer | 504.8K | — | — | — | 189.3K | 14.7K | 907.4K | 0.00% | ↗ |
| 60 | 2012 | Michael Coffee Chief Business Officer | 309.0K | — | 132.5K | — | 81.1K | 76.1K | 598.7K | 22.13% | ↗ |
| 61 | 2012 | Michael Gennaro Chief Financial Officer | — | — | — | — | — | 594.9K | 594.9K | 0.00% | ↗ |
| 62 | 2012 | Kirk Johnson, Ph.D. Chief Scientific Officer | 293.6K | — | 132.5K | — | 77.1K | 61.0K | 564.0K | 23.48% | ↗ |
| 63 | 2012 | Masatsune Okajima Vice President and Head of Japanese Office | 293.6K | — | — | — | 77.1K | 21.4K | 524.4K | 0.00% | ↗ |
| 64 | 2012 | Kazuko Matsuda, M.D., Ph.D. Chief Medical Officer | 293.6K | — | — | — | 67.4K | 22.7K | 516.1K | 0.00% | ↗ |
| 65 | 2011 | Yuichi Iwaki, M.D., Ph.D. President and Chief Executive Officer | 490.1K | — | — | — | 203.4K | 14.7K | 1.04M | 0.00% | ↗ |
| 66 | 2011 | Yuichi Iwaki, M.D., Ph.D. President and Chief and Executive Officer | 490.1K | — | 332.0K | — | 80.9K | 14.7K | 917.6K | 36.18% | ↗ |
| 67 | 2011 | Kazuko Matsuda, M.D., Ph.D., MPH Chief Medical Officer | 255.0K | — | — | — | 85.9K | 12.1K | 666.7K | 0.00% | ↗ |
| 68 | 2011 | Michael Coffee Chief Business Officer | 300.0K | — | 262.0K | — | 34.7K | 67.5K | 664.2K | 39.45% | ↗ |
| 69 | 2011 | Kirk Johnson, Ph.D. Chief Scientific Officer | 285.0K | — | 262.0K | — | 32.9K | 59.2K | 639.1K | 41.00% | ↗ |
| 70 | 2011 | Kazuko Matsuda, M.D., Ph.D. Chief Medical Officer | 255.0K | — | 313.7K | — | 36.0K | 12.1K | 606.8K | 51.69% | ↗ |
| 71 | 2011 | Masatsune Okajima Vice President and Head of Japanese Office | 285.0K | — | 262.0K | — | 32.9K | 17.8K | 597.7K | 43.84% | ↗ |
| 72 | 2011 | Shintaro Asako, CPA Former Chief Financial Officer | 23.8K | — | — | — | — | 237.5K | 261.3K | 0.00% | ↗ |
| 73 | 2011 | Michael Gennaro Chief Financial Officer | — | — | — | — | — | 215.9K | 215.9K | 0.00% | ↗ |
| 74 | 2011 | Michael Gennaro Chief Financial Officer | — | — | — | — | — | 215.7K | 215.7K | 0.00% | ↗ |
| 75 | 2010 | Kirk Johnson, Ph.D. Chief Scientific Officer | 261.3K | — | — | — | — | 68.6K | 763.8K | 0.00% | ↗ |
| 76 | 2010 | Kirk Johnson, Ph.D. Chief Scientific Officer | 261.3K | — | — | — | — | 68.6K | 763.8K | 0.00% | ↗ |
| 77 | 2010 | Yuichi Iwaki, M.D., Ph.D. . President and Chief Executive Officer | 490.1K | — | — | — | — | 14.7K | 759.1K | 0.00% | ↗ |
| 78 | 2010 | Yuichi Iwaki, M.D., Ph.D. President and Chief Executive Officer | 490.1K | — | — | — | — | 14.7K | 759.1K | 0.00% | ↗ |
| 79 | 2010 | Michael Coffee Chief Business Officer | 164.3K | — | — | — | — | 28.8K | 494.5K | 0.00% | ↗ |
| 80 | 2010 | Michael Coffee Chief Business Officer | 164.3K | — | — | — | — | 28.8K | 494.5K | 0.00% | ↗ |
| 81 | 2010 | Masatsune Okajima Vice President and Head of Japanese Office | 285.0K | — | — | — | — | 16.7K | 456.6K | 0.00% | ↗ |
| 82 | 2010 | Shintaro Asako, CPA Former Chief Financial Officer | 285.0K | — | — | — | — | 14.7K | 454.6K | 0.00% | ↗ |
| 83 | 2009 | Yuichi Iwaki, M.D., Ph.D. . President and Chief Executive Officer | 473.5K | — | — | — | 236.7K | 14.7K | 838.0K | 0.00% | ↗ |
| 84 | 2009 | Yuichi Iwaki, M.D., Ph.D. President and Chief Executive Officer | 473.5K | — | — | — | 236.7K | 14.7K | 838.0K | 0.00% | ↗ |
| 85 | 2009 | Richard Gammans, Ph.D. Former Chief Development Officer | 177.1K | — | — | — | — | 409.8K | 656.5K | 0.00% | ↗ |
| 86 | 2009 | Shintaro Asako, CPA Former Chief Financial Officer | 243.3K | — | — | — | 100.0K | 14.7K | 427.6K | 0.00% | ↗ |
| 87 | 2009 | Shintaro Asako, CPA Chief Financial Officer | 243.3K | — | — | — | 100.0K | 14.7K | 427.6K | 0.00% | ↗ |
| 88 | 2009 | Masatsune Okajima Vice President and Head of Japanese Office | 248.6K | — | — | — | 100.0K | 16.7K | 413.1K | 0.00% | ↗ |
| 89 | 2009 | Michael Kalafer, M.D. Former Chief Medical Officer | 121.7K | — | — | — | — | 240.6K | 410.1K | 0.00% | ↗ |
| 90 | 2008 | Yuichi Iwaki, M.D., Ph.D. . President and Chief Executive Officer | 464.2K | — | — | — | 139.3K | 13.8K | 926.7K | 0.00% | ↗ |
| 91 | 2008 | Yuichi Iwaki, M.D., Ph.D. President and Chief Executive Officer | 464.2K | — | — | — | 139.3K | 13.8K | 926.7K | 0.00% | ↗ |
| 92 | 2008 | Richard Gammans, Ph.D. Former Chief Development Officer | 382.0K | — | — | — | 80.8K | 13.8K | 705.1K | 0.00% | ↗ |
| 93 | 2008 | Richard Gammans, Ph.D. Chief Development Officer | 382.0K | — | — | — | 80.8K | 13.8K | 705.1K | 0.00% | ↗ |
| 94 | 2008 | Michael Kalafer, M.D. Former Chief Medical Officer | 260.0K | — | — | — | 51.8K | 13.8K | 494.1K | 0.00% | ↗ |
| 95 | 2008 | Michael Kalafer, M.D. Former Chief Medical Officer | 260.0K | — | — | — | 51.8K | 13.8K | 494.1K | 0.00% | ↗ |
| 96 | 2008 | Shintaro Asako, CPA Former Chief Financial Officer | 236.2K | — | — | — | 50.2K | 13.8K | 476.4K | 0.00% | ↗ |
| 97 | 2008 | Shintaro Asako, CPA Chief Financial Officer | 236.2K | — | — | — | 50.2K | 13.8K | 476.4K | 0.00% | ↗ |
| 98 | 2008 | Masatsune Okajima Vice President and Head of Japanese Office | 241.3K | — | — | — | 45.8K | 17.0K | 418.4K | 0.00% | ↗ |
| 99 | 2007 | Yuichi Iwaki, M.D., Ph.D. President and Chief Executive Officer | 452.0K | 90.4K | — | — | — | 54.5K | 596.9K | 0.00% | ↗ |
| 100 | 2007 | Yuichi Iwaki, M.D., Ph.D. . President and Chief Executive Officer | 452.0K | 90.4K | — | — | — | 54.5K | 596.9K | 0.00% | ↗ |
| 101 | 2007 | Richard Gammans, Ph.D. Chief Development Officer | 297.0K | 52.1K | — | — | — | 113.4K | 462.7K | 0.00% | ↗ |
| 102 | 2007 | Richard Gammans, Ph.D. Former Chief Development Officer | 297.0K | 52.1K | — | — | — | 113.4K | 462.7K | 0.00% | ↗ |
| 103 | 2007 | Richard Gammans, Ph.D. Chief Business Officer | 297.0K | 52.1K | — | — | — | 113.6K | 462.7K | 0.00% | ↗ |
| 104 | 2007 | Kenneth Locke, Ph.D. Chief Scientific Officer | 260.0K | 36.4K | — | — | — | 36.7K | 333.1K | 0.00% | ↗ |
| 105 | 2007 | Shintaro Asako, CPA Chief Financial Officer | 230.0K | 40.3K | — | — | — | 32.9K | 303.2K | 0.00% | ↗ |
| 106 | 2007 | Masatsune Okajima Vice President and Head of Japanese Office | 235.0K | 32.9K | — | — | — | 19.7K | 287.6K | 0.00% | ↗ |
| 107 | 2006 | Yuichi Iwaki, M.D., Ph.D. President and Chief Executive Officer | 350.0K | 150.0K | — | — | — | — | 3.09M | 0.00% | ↗ |
| 108 | 2006 | Richard Gammans, Ph.D. Chief Business Officer | 280.0K | 84.0K | — | — | — | 102.1K | 1.83M | 0.00% | ↗ |
| 109 | 2006 | Richard Gammans, Ph.D. Chief Development Officer | 280.0K | 84.0K | — | — | — | 102.1K | 1.83M | 0.00% | ↗ |
| 110 | 2006 | Kenneth Locke, Ph.D. Chief Scientific Officer | 245.0K | 73.0K | — | — | — | 31.4K | 1.52M | 0.00% | ↗ |
| 111 | 2006 | Masatsune Okajima Vice President and Head of Japanese Office | 73.3K | 60.0K | — | — | — | 5.0K | 1.21M | 0.00% | ↗ |
| 112 | 2006 | Shintaro Asako, CPA Chief Financial Officer | 173.3K | 73.0K | — | — | — | 31.8K | 1.19M | 0.00% | ↗ |
| 113 | 2005 | Shintaro Asako, CPA Vice President, Accounting and Administration | 68.6K | 30.0K | — | — | — | 15.3K | 113.9K | 0.00% | ↗ |
| 114 | 2004 | Brian Anderson Chief Business Officer | — | — | — | — | — | — | — | — | ↗ |
| 115 | 2004 | Richard E. Gammans, Ph.D. Chief Development Officer | — | — | — | — | — | — | — | — | ↗ |
| 116 | 2004 | Mark Lotz Vice President, Regulatory Affairs | — | — | — | — | — | — | — | — | ↗ |
| 117 | 2004 | Joji Suzuki, M.D., Ph.D. Vice President, Finance | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Yuichi Iwaki | Co-Founder, President, Chief Executive Officer & Chairman | 1M | — |
| Kazuko Matsuda | Senior VP, Chief Medical Officer & Director | 741.2K | — |
| David H. Crean | Chief Business Officer | 120.0K | — |
| Jason J. Kruger | Chief Financial Officer & Principal Financial Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MNOV
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
